Delcath Systems: Activist Linkedto Questions Company's Need for ATM Dilution

Sept. 10, 2014 - PRLog -- Dear Delcath Investors and Shareholders,

We and several other investors collectively own or control about 4.7 percent of the company's common stock. In relation to the management and board of directors, we the shareholders own far more shares than those still in charge of this copany currently.

Why have we seen no resubmission or any news about said event by company regarding its chemosat product to the FDA? The compantly management  and board are paid far too excesively for such a small market cap. We believe the compensation committee members must do their job and ensure salaries reflect stock underperformance of this company for a few years. Belt tightening needs to take place while we await actual progress from the company.

We have heard back from many investors in emails and telephone calls.

One of the most common complaints we have heard back about the company is its insistence on keeping up the at the market program while the company is burning through cash.   We and many other investors believe this ATM program must be immediately halted in order to create both short and long term value for shareholders.

Our unsolicited non-binding proposal for the company for $3 per share still stands and we look forward to hearing back from the board in reviewing our recent offer.

Any shareholders wanting to express support can call 1.203.297.8268.

We do intend to call for a special meeting of shareholders calling for a sale of the vompanty or strategic alternatives once some more shareholders come forward soon.

Regards,

Neil Fromer

Linkedto Partners

Contact:

Jonathan Sanders

JonathanSand@bayttrust.com

1.203. 297.8268